NASDAQ: MAZEMaze Therapeutics Inc Stock
$26.92-0.71 (-2.57%)
Updated Jul 31, 2026
MAZE Price
$26.92
Fair Value Price
$3.86
Market Cap
$1.49B
52 Week Low
$12.81
52 Week High
$53.65
P/E
-10.85x
P/B
4.36x
P/S
80.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.00M
Earnings
-$122.54M
Gross Margin
100%
Operating Margin
-608.38%
Profit Margin
-612.7%
Debt to Equity
0.23
Operating Cash Flow
-$122M
Beta
0.9
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MAZE Overview
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MAZE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MAZE
Ranked#150 of 460
Ranked#150 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $252.86 | A | |
| $11.21 | A | |
| $114.49 | A |
Be the first to know about important MAZE news, forecast changes, insider trades & much more!
MAZE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MAZE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MAZE ($26.92) is overvalued by 597.18% relative to our estimate of its Fair Value price of $3.86 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MAZE ($26.92) is not significantly undervalued (597.18%) relative to our estimate of its Fair Value price of $3.86 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MAZE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MAZE due diligence checks available for Premium users.
Valuation
MAZE fair value
Fair Value of MAZE stock based on Discounted Cash Flow (DCF)
Price
$26.92
Fair Value
$3.86
Overvalued by
597.18%
MAZE ($26.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MAZE ($26.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MAZE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MAZE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.85x
Industry
20.12x
Market
16.06x
MAZE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.36x
Industry
5.23x
MAZE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MAZE's financial health
Profit margin
Revenue
$20.0M
Net Income
-$24.2M
Profit Margin
-121%
MAZE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MAZE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$419.7M
Liabilities
$78.0M
Debt to equity
0.23
MAZE's short-term assets ($379.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MAZE's short-term assets ($379.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MAZE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$39.1M
Investing
$6.3M
Financing
$42.4M
MAZE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MAZE vs Biotech Stocks
Maze Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.